78 related articles for article (PubMed ID: 8740098)
21. Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system.
Segarra I; Movshin DA; Zarif L
J Pharm Sci; 2002 Aug; 91(8):1827-37. PubMed ID: 12115810
[TBL] [Abstract][Full Text] [Related]
22. Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B.
Strenger V; Meinitzer A; Donnerer J; Hofer N; Dornbusch HJ; Wanz U; Seidel MG; Sperl D; Lackner H; Schwinger W; Sovinz P; Benesch M; Urban C
J Antimicrob Chemother; 2014 Sep; 69(9):2522-6. PubMed ID: 24891430
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
Ayestarán A; López RM; Montoro JB; Estíbalez A; Pou L; Julià A; López A; Pascual B
Antimicrob Agents Chemother; 1996 Mar; 40(3):609-12. PubMed ID: 8851579
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: Population approach in Japanese pediatrics.
Ohata Y; Tomita Y; Suzuki K; Maniwa T; Yano Y; Sunakawa K
Drug Metab Pharmacokinet; 2015 Dec; 30(6):400-9. PubMed ID: 26645511
[TBL] [Abstract][Full Text] [Related]
25. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM
J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140
[TBL] [Abstract][Full Text] [Related]
26. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.
Adedoyin A; Swenson CE; Bolcsak LE; Hellmann A; Radowska D; Horwith G; Janoff AS; Branch RA
Antimicrob Agents Chemother; 2000 Oct; 44(10):2900-2. PubMed ID: 10991885
[TBL] [Abstract][Full Text] [Related]
27. Amphotericin B disposition after aerosol inhalation in lung transplant recipients.
Marra F; Partovi N; Wasan KM; Kwong EH; Ensom MH; Cassidy SM; Fradet G; Levy RD
Ann Pharmacother; 2002 Jan; 36(1):46-51. PubMed ID: 11816256
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.
Adedoyin A; Bernardo JF; Swenson CE; Bolsack LE; Horwith G; DeWit S; Kelly E; Klasterksy J; Sculier JP; DeValeriola D; Anaissie E; Lopez-Berestein G; Llanos-Cuentas A; Boyle A; Branch RA
Antimicrob Agents Chemother; 1997 Oct; 41(10):2201-8. PubMed ID: 9333048
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of amphotericin B in children with malignant diseases.
Nath CE; McLachlan AJ; Shaw PJ; Gunning R; Earl JW
Br J Clin Pharmacol; 2001 Dec; 52(6):671-80. PubMed ID: 11736878
[TBL] [Abstract][Full Text] [Related]
30. Serum pharmacology of amphotericin B applied in lipid emulsions.
Heinemann V; Kähny B; Jehn U; Mühlbayer D; Debus A; Wachholz K; Bosse D; Kolb HJ; Wilmanns W
Antimicrob Agents Chemother; 1997 Apr; 41(4):728-32. PubMed ID: 9087478
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and tolerance of liposomal amphotericin B in patients.
Gokhale PC; Barapatre RJ; Advani SH; Kshirsagar NA; Pandya SK
J Antimicrob Chemother; 1993 Jul; 32(1):133-9. PubMed ID: 8226404
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of amphotericin B lipid complex in neonates.
Würthwein G; Groll AH; Hempel G; Adler-Shohet FC; Lieberman JM; Walsh TJ
Antimicrob Agents Chemother; 2005 Dec; 49(12):5092-8. PubMed ID: 16304177
[TBL] [Abstract][Full Text] [Related]
33. New and simple method for estimating metildigoxin dosing regimens by multiple trough screen analysis.
Yukawa E
Int J Clin Pharmacol Ther; 1995 Nov; 33(11):605-11. PubMed ID: 8688985
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of amphotericin B in rats as a function of dose following constant-rate intravenous infusion.
Chow HH; Wu Y; Mayersohn M
Biopharm Drug Dispos; 1995 Aug; 16(6):461-73. PubMed ID: 7579028
[TBL] [Abstract][Full Text] [Related]
35. Lipid formulations of amphotericin B.
Jones E; Goldman M
Cleve Clin J Med; 1998 Sep; 65(8):423-7. PubMed ID: 9769563
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.
Amantea MA; Bowden RA; Forrest A; Working PK; Newman MS; Mamelok RD
Antimicrob Agents Chemother; 1995 Sep; 39(9):2042-7. PubMed ID: 8540713
[TBL] [Abstract][Full Text] [Related]
37. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.
Nath CE; Shaw PJ; Gunning R; McLachlan AJ; Earl JW
Antimicrob Agents Chemother; 1999 Jun; 43(6):1417-23. PubMed ID: 10348763
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens.
Hope WW; Goodwin J; Felton TW; Ellis M; Stevens DA
Antimicrob Agents Chemother; 2012 Oct; 56(10):5303-8. PubMed ID: 22869566
[TBL] [Abstract][Full Text] [Related]
39. Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases.
Hong Y; Shaw PJ; Tattam BN; Nath CE; Earl JW; Stephen KR; McLachlan AJ
Eur J Clin Pharmacol; 2007 Feb; 63(2):165-72. PubMed ID: 17180621
[TBL] [Abstract][Full Text] [Related]
40. Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion.
Demartini G; Lequaglie C; Brega Massone PP; Scaglione F; Fraschini F
J Chemother; 2005 Feb; 17(1):82-5. PubMed ID: 15828449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
